{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:08:13Z","timestamp":1794632893454,"version":"4.9.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Gangliosides are highly enriched in the brain and are critical for its normal development and function. However, in some rare neurometabolic diseases, a deficiency in lysosomal ganglioside hydrolysis is pathogenic and leads to early-onset neurodegeneration, neuroinflammation, demyelination, and dementia. Increasing evidence also suggests that more subtle ganglioside accumulation contributes to the pathogenesis of more common neurological disorders including Alzheimer\u2019s disease (AD). Notably, ganglioside GM3 levels are elevated in the brains of AD patients and in several mouse models of AD, and plasma GM3 levels positively correlate with disease severity in AD patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Tg2576 AD model mice were fed chow formulated with a small molecule inhibitor of glucosylceramide synthase (GCSi) to determine whether reducing glycosphingolipid synthesis affected aberrant GM3 accumulation, amyloid burden, and disease manifestations in cognitive impairment. GM3 was measured with LC-MS, amyloid burden with ELISA and amyloid red staining, and memory was assessed using the contextual fear chamber test.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>GCSi mitigated soluble A\u03b242 accumulation in the brains of AD model mice when treatment was started prophylactically. Remarkably, GCSi treatment also reduced soluble A\u03b242 levels and amyloid plaque burden in aged (i.e., 70 weeks old) AD mice with preexisting neuropathology. Our analysis of contextual memory in Tg2576 mice showed that impairments in remote (cortical-dependent) memory consolidation preceded deficits in short-term (hippocampal-dependent) contextual memory, which was consistent with soluble A\u03b242 accumulation occurring more rapidly in the cortex of AD mice compared to the hippocampus. Notably, GCSi treatment significantly stabilized remote memory consolidation in AD mice\u2014especially in mice with enhanced cognitive training. This finding was consistent with GCSi treatment lowering aberrant GM3 accumulation in the cortex of AD mice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Collectively, our results indicate that glycosphingolipids regulated by GCS are important modulators of A\u03b2 neuropathology and that glycosphingolipid homeostasis plays a critical role in the consolidation of remote memories.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-022-00966-0","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T09:02:38Z","timestamp":1643706158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Glucosylceramide synthase inhibition reduces ganglioside GM3 accumulation, alleviates amyloid neuropathology, and stabilizes remote contextual memory in a mouse model of Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4466-7213","authenticated-orcid":false,"given":"James C.","family":"Dodge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Tamsett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Treleaven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana V.","family":"Taksir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Piepenhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Pablo","family":"Sardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seng H.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamya S.","family":"Shihabuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,1]]},"reference":[{"key":"966_CR1","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1089\/aid.1998.14.1065","volume":"14","author":"LM Andersson","year":"1998","unstructured":"Andersson LM, Fredman P, Lekman A, Rosengren L, Gisslen M. Increased cerebrospinal fluid ganglioside GD3 concentrations as a marker of microglial activation in HIV type 1 infection. AIDS Res Hum Retroviruses. 1998;14:1065\u20139. https:\/\/doi.org\/10.1089\/aid.1998.14.1065.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"966_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1034\/j.1600-0404.107.s179.7.x","volume":"179","author":"E Arnaiz","year":"2003","unstructured":"Arnaiz E, Almkvist O. Neuropsychological features of mild cognitive impairment and preclinical Alzheimer\u2019s disease. Acta Neurol Scand Suppl. 2003;179:34\u201341.","journal-title":"Acta Neurol Scand Suppl"},{"key":"966_CR3","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.bbamcr.2008.12.001","volume":"1793","author":"A Ballabio","year":"2009","unstructured":"Ballabio A, Gieselmann V. Lysosomal disorders: from storage to cellular damage. Biochim Biophys Acta. 2009;1793:684\u201396. https:\/\/doi.org\/10.1016\/j.bbamcr.2008.12.001.","journal-title":"Biochim Biophys Acta"},{"key":"966_CR4","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.neurobiolaging.2007.12.022","volume":"30","author":"A Bernardo","year":"2009","unstructured":"Bernardo A, Harrison FE, McCord M, Zhao J, Bruchey A, Davies SS, et al. Elimination of GD3 synthase improves memory and reduces amyloid-beta plaque load in transgenic mice. Neurobiol Aging. 2009;30:1777\u201391. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2007.12.022.","journal-title":"Neurobiol Aging"},{"key":"966_CR5","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/jnc.15136","volume":"156","author":"S Blumenreich","year":"2021","unstructured":"Blumenreich S, Yaacobi C, Vardi A, Barav OB, Vitner EB, Park H, et al. Substrate reduction therapy using Genz-667161 reduces levels of pathogenic components in a mouse model of neuronopathic forms of Gaucher disease. J Neurochem. 2021;156:692\u2013701. https:\/\/doi.org\/10.1111\/jnc.15136.","journal-title":"J Neurochem"},{"key":"966_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043310","volume":"7","author":"MA Cabrera-Salazar","year":"2012","unstructured":"Cabrera-Salazar MA, Deriso M, Bercury SD, Li L, Lydon JT, Weber W, et al. Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. PLoS One. 2012;7:e43310. https:\/\/doi.org\/10.1371\/journal.pone.0043310.","journal-title":"PLoS One"},{"key":"966_CR7","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.bbagen.2018.03.011","volume":"1862","author":"S Caughlin","year":"2018","unstructured":"Caughlin S, Maheshwari S, Agca Y, Agca C, Harris AJ, Jurcic K, et al. Membrane-lipid homeostasis in a prodromal rat model of Alzheimer\u2019s disease: characteristic profiles in ganglioside distributions during aging detected using MALDI imaging mass spectrometry. Biochim Biophys Acta Gen Subj. 2018;1862:1327\u201338. https:\/\/doi.org\/10.1016\/j.bbagen.2018.03.011.","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"966_CR8","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1074\/jbc.M111.274142","volume":"287","author":"RB Chan","year":"2012","unstructured":"Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA, et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem. 2012;287:2678\u201388. https:\/\/doi.org\/10.1074\/jbc.M111.274142.","journal-title":"J Biol Chem"},{"key":"966_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/0304-3940(88)90577-0","volume":"86","author":"J Chapman","year":"1988","unstructured":"Chapman J, Sela BA, Wertman E, Michaelson DM. Antibodies to ganglioside GM1 in patients with Alzheimer\u2019s disease. Neurosci Lett. 1988;86:235\u201340. https:\/\/doi.org\/10.1016\/0304-3940(88)90577-0.","journal-title":"Neurosci Lett"},{"key":"966_CR10","doi-asserted-by":"publisher","first-page":"22987","DOI":"10.1074\/jbc.272.37.22987","volume":"272","author":"LP Choo-Smith","year":"1997","unstructured":"Choo-Smith LP, Garzon-Rodriguez W, Glabe CG, Surewicz WK. Acceleration of amyloid fibril formation by specific binding of Abeta-(1-40) peptide to ganglioside-containing membrane vesicles. J Biol Chem. 1997;272:22987\u201390. https:\/\/doi.org\/10.1074\/jbc.272.37.22987.","journal-title":"J Biol Chem"},{"key":"966_CR11","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ymgme.2013.11.012","volume":"111","author":"WL Chuang","year":"2014","unstructured":"Chuang WL, Pacheco J, Cooper S, McGovern MM, Cox GF, Keutzer J, et al. Lyso-sphingomyelin is elevated in dried blood spots of Niemann-Pick B patients. Mol Genet Metab. 2014;111:209\u201311. https:\/\/doi.org\/10.1016\/j.ymgme.2013.11.012.","journal-title":"Mol Genet Metab"},{"key":"966_CR12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1001\/archneur.1989.00520400054019","volume":"46","author":"PB Crino","year":"1989","unstructured":"Crino PB, Ullman MD, Vogt BA, Bird ED, Volicer L. Brain gangliosides in dementia of the Alzheimer type. Arch Neurol. 1989;46:398\u2013401. https:\/\/doi.org\/10.1001\/archneur.1989.00520400054019.","journal-title":"Arch Neurol"},{"key":"966_CR13","doi-asserted-by":"publisher","first-page":"32046","DOI":"10.1074\/jbc.M201750200","volume":"277","author":"KN Dahlgren","year":"2002","unstructured":"Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem. 2002;277:32046\u201353. https:\/\/doi.org\/10.1074\/jbc.M201750200.","journal-title":"J Biol Chem"},{"key":"966_CR14","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1007\/s11064-017-2266-0","volume":"42","author":"R Dai","year":"2017","unstructured":"Dai R, Zhang S, Duan W, Wei R, Chen H, Cai W, et al. Enhanced Autophagy Contributes to Protective Effects of GM1 Ganglioside Against Abeta1-42-Induced Neurotoxicity and Cognitive Deficits. Neurochem Res. 2017;42:2417\u201326. https:\/\/doi.org\/10.1007\/s11064-017-2266-0.","journal-title":"Neurochem Res"},{"key":"966_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.nbd.2007.05.003","volume":"27","author":"PA Desplats","year":"2007","unstructured":"Desplats PA, Denny CA, Kass KE, Gilmartin T, Head SR, Sutcliffe JG, et al. Glycolipid and ganglioside metabolism imbalances in Huntington's disease. Neurobiol Dis. 2007;27:265\u201377. https:\/\/doi.org\/10.1016\/j.nbd.2007.05.003.","journal-title":"Neurobiol Dis"},{"key":"966_CR16","doi-asserted-by":"publisher","first-page":"8100","DOI":"10.1073\/pnas.1508767112","volume":"112","author":"JC Dodge","year":"2015","unstructured":"Dodge JC, Treleaven CM, Pacheco J, Cooper S, Bao C, Abraham M, et al. Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2015;112:8100\u20135. https:\/\/doi.org\/10.1073\/pnas.1508767112.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"966_CR17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.neurobiolaging.2019.01.020","volume":"77","author":"M Dukhinova","year":"2019","unstructured":"Dukhinova M, Veremeyko T, Yung AWY, Kuznetsova IS, Lau TYB, Kopeikina E, et al. Fresh evidence for major brain gangliosides as a target for the treatment of Alzheimer\u2019s disease. Neurobiol Aging. 2019;77:128\u201343. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2019.01.020.","journal-title":"Neurobiol Aging"},{"key":"966_CR18","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1016\/j.bbadis.2017.08.013","volume":"1863","author":"EJ Fernandez-Perez","year":"2017","unstructured":"Fernandez-Perez EJ, Sepulveda FJ, Peoples R, Aguayo LG. Role of membrane GM1 on early neuronal membrane actions of Abeta during onset of Alzheimer\u2019s disease. Biochim Biophys Acta Mol Basis Dis. 2017;1863:3105\u201316. https:\/\/doi.org\/10.1016\/j.bbadis.2017.08.013.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"966_CR19","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1001\/archpsyc.55.9.809","volume":"55","author":"S Gao","year":"1998","unstructured":"Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry. 1998;55:809\u201315. https:\/\/doi.org\/10.1001\/archpsyc.55.9.809.","journal-title":"Arch Gen Psychiatry"},{"key":"966_CR20","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/brain\/awt270","volume":"136","author":"GV Harlalka","year":"2013","unstructured":"Harlalka GV, Lehman A, Chioza B, Baple EL, Maroofian R, Cross H, et al. Mutations in B4GALNT1 (GM2 synthase) underlie a new disorder of ganglioside biosynthesis. Brain. 2013;136:3618\u201324. https:\/\/doi.org\/10.1093\/brain\/awt270.","journal-title":"Brain"},{"key":"966_CR21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3389\/fnmol.2018.00206","volume":"11","author":"S Herzer","year":"2018","unstructured":"Herzer S, Hagan C, von Gerichten J, Dieterle V, Munteanu B, Sandhoff R, et al. Deletion of specific sphingolipids in distinct neurons improves spatial memory in a mouse model of Alzheimer\u2019s disease. Front Mol Neurosci. 2018;11:206. https:\/\/doi.org\/10.3389\/fnmol.2018.00206.","journal-title":"Front Mol Neurosci"},{"key":"966_CR22","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.1038\/s41467-020-19473-7","volume":"11","author":"K Huynh","year":"2020","unstructured":"Huynh K, Lim WLF, Giles C, Jayawardana KS, Salim A, Mellett NA, et al. Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer\u2019s disease. Nat Commun. 2020;11:5698. https:\/\/doi.org\/10.1038\/s41467-020-19473-7.","journal-title":"Nat Commun"},{"key":"966_CR23","doi-asserted-by":"publisher","first-page":"24985","DOI":"10.1074\/jbc.M100252200","volume":"276","author":"A Kakio","year":"2001","unstructured":"Kakio A, Nishimoto SI, Yanagisawa K, Kozutsumi Y, Matsuzaki K. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J Biol Chem. 2001;276:24985\u201390. https:\/\/doi.org\/10.1074\/jbc.M100252200.","journal-title":"J Biol Chem"},{"key":"966_CR24","first-page":"269","volume":"40","author":"S Kalanj","year":"1991","unstructured":"Kalanj S, Kracun I, Rosner H, Cosovic C. Regional distribution of brain gangliosides in Alzheimer\u2019s disease. Neurol Croat. 1991;40:269\u201381.","journal-title":"Neurol Croat"},{"key":"966_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0304-3940(94)90027-2","volume":"174","author":"K Kawai","year":"1994","unstructured":"Kawai K, Kuroda S, Watarai S, Takahashi H, Ikuta F. Occurrence of GD3 ganglioside in reactive astrocytes--an immunocytochemical study in the rat brain. Neurosci Lett. 1994;174:225\u20137. https:\/\/doi.org\/10.1016\/0304-3940(94)90027-2.","journal-title":"Neurosci Lett"},{"key":"966_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1523\/JNEUROSCI.21-02-00372.2001","volume":"21","author":"T Kawarabayashi","year":"2001","unstructured":"Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer\u2019s disease. J Neurosci. 2001;21:372\u201381.","journal-title":"J Neurosci"},{"key":"966_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1021\/acschemneuro.9b00532","volume":"11","author":"I Kaya","year":"2020","unstructured":"Kaya I, Jennische E, Dunevall J, Lange S, Ewing AG, Malmberg P, et al. Spatial lipidomics reveals region and long chain base specific accumulations of monosialogangliosides in amyloid plaques in familial Alzheimer\u2019s disease mice (5xFAD) brain. ACS Chem Neurosci. 2020;11:14\u201324. https:\/\/doi.org\/10.1021\/acschemneuro.9b00532.","journal-title":"ACS Chem Neurosci"},{"key":"966_CR28","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/0197-0186(92)90058-y","volume":"20","author":"I Kracun","year":"1992","unstructured":"Kracun I, Kalanj S, Talan-Hranilovic J, Cosovic C. Cortical distribution of gangliosides in Alzheimer\u2019s disease. Neurochem Int. 1992;20:433\u20138. https:\/\/doi.org\/10.1016\/0197-0186(92)90058-y.","journal-title":"Neurochem Int"},{"key":"966_CR29","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.neuint.2011.06.007","volume":"59","author":"F Kreutz","year":"2011","unstructured":"Kreutz F, Frozza RL, Breier AC, de Oliveira VA, Horn AP, Pettenuzzo LF, et al. Amyloid-beta induced toxicity involves ganglioside expression and is sensitive to GM1 neuroprotective action. Neurochem Int. 2011;59:648\u201355. https:\/\/doi.org\/10.1016\/j.neuint.2011.06.007.","journal-title":"Neurochem Int"},{"key":"966_CR30","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3389\/fneur.2019.00859","volume":"10","author":"PJ Magistretti","year":"2019","unstructured":"Magistretti PJ, Geisler FH, Schneider JS, Li PA, Fiumelli H, Sipione S. Gangliosides: treatment avenues in neurodegenerative disease. Front Neurol. 2019;10:859. https:\/\/doi.org\/10.3389\/fneur.2019.00859.","journal-title":"Front Neurol"},{"key":"966_CR31","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ymthe.2019.05.018","volume":"27","author":"J Marshall","year":"2019","unstructured":"Marshall J, Nietupski JB, Park H, Cao J, Bangari DS, Silvescu C, et al. Substrate reduction therapy for sandhoff disease through inhibition of glucosylceramide synthase activity. Mol Ther. 2019;27:1495\u2013506. https:\/\/doi.org\/10.1016\/j.ymthe.2019.05.018.","journal-title":"Mol Ther"},{"key":"966_CR32","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1021\/bi982345o","volume":"38","author":"K Matsuzaki","year":"1999","unstructured":"Matsuzaki K, Horikiri C. Interactions of amyloid beta-peptide (1-40) with ganglioside-containing membranes. Biochemistry. 1999;38:4137\u201342. https:\/\/doi.org\/10.1021\/bi982345o.","journal-title":"Biochemistry"},{"key":"966_CR33","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M","volume":"46","author":"CA McLean","year":"1999","unstructured":"McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer\u2019s disease. Ann Neurol. 1999;46:860\u20136 https:\/\/doi.org\/10.1002\/1531-8249(199912)46:6<860::aid-ana8>3.0.co;2-m.","journal-title":"Ann Neurol"},{"key":"966_CR34","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.bbapap.2018.09.010","volume":"1867","author":"W Michno","year":"2019","unstructured":"Michno W, Wehrli PM, Zetterberg H, Blennow K, Hanrieder J. GM1 locates to mature amyloid structures implicating a prominent role for glycolipid-protein interactions in Alzheimer pathology. Biochim Biophys Acta Proteins Proteom. 2019;1867:458\u201367. https:\/\/doi.org\/10.1016\/j.bbapap.2018.09.010.","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"key":"966_CR35","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1007\/s00018-005-5188-y","volume":"62","author":"I Mocchetti","year":"2005","unstructured":"Mocchetti I. Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins. Cell Mol Life Sci. 2005;62:2283\u201394. https:\/\/doi.org\/10.1007\/s00018-005-5188-y.","journal-title":"Cell Mol Life Sci"},{"key":"966_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1471-4159.2004.02849.x","volume":"92","author":"M Molander-Melin","year":"2005","unstructured":"Molander-Melin M, Blennow K, Bogdanovic N, Dellheden B, Mansson JE, Fredman P. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J Neurochem. 2005;92:171\u201382. https:\/\/doi.org\/10.1111\/j.1471-4159.2004.02849.x.","journal-title":"J Neurochem"},{"key":"966_CR37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.ymgme.2012.01.020","volume":"105","author":"JB Nietupski","year":"2012","unstructured":"Nietupski JB, Pacheco JJ, Chuang WL, Maratea K, Li L, Foley J, et al. Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice. Mol Genet Metab. 2012;105:621\u20138. https:\/\/doi.org\/10.1016\/j.ymgme.2012.01.020.","journal-title":"Mol Genet Metab"},{"key":"966_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.mcn.2016.06.009","volume":"75","author":"A Noel","year":"2016","unstructured":"Noel A, Ingrand S, Barrier L. Anti-amyloidogenic effects of glycosphingolipid synthesis inhibitors occur independently of ganglioside alterations. Mol Cell Neurosci. 2016;75:63\u201370. https:\/\/doi.org\/10.1016\/j.mcn.2016.06.009.","journal-title":"Mol Cell Neurosci"},{"key":"966_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121356","volume":"10","author":"N Oikawa","year":"2015","unstructured":"Oikawa N, Matsubara T, Fukuda R, Yasumori H, Hatsuta H, Murayama S, et al. Imbalance in fatty-acid-chain length of gangliosides triggers Alzheimer amyloid deposition in the precuneus. PLoS One. 2015;10:e0121356. https:\/\/doi.org\/10.1371\/journal.pone.0121356.","journal-title":"PLoS One"},{"key":"966_CR40","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/WNR.0b013e32832e4b9d","volume":"20","author":"N Oikawa","year":"2009","unstructured":"Oikawa N, Yamaguchi H, Ogino K, Taki T, Yuyama K, Yamamoto N, et al. Gangliosides determine the amyloid pathology of Alzheimer\u2019s disease. Neuroreport. 2009;20:1043\u20136. https:\/\/doi.org\/10.1097\/WNR.0b013e32832e4b9d.","journal-title":"Neuroreport"},{"key":"966_CR41","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.ncl.2013.04.007","volume":"31","author":"GM Pastores","year":"2013","unstructured":"Pastores GM, Maegawa GH. Clinical neurogenetics: neuropathic lysosomal storage disorders. Neurol Clin. 2013;31:1051\u201371. https:\/\/doi.org\/10.1016\/j.ncl.2013.04.007.","journal-title":"Neurol Clin"},{"key":"966_CR42","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000338181","volume":"33","author":"Z Pernber","year":"2012","unstructured":"Pernber Z, Blennow K, Bogdanovic N, Mansson JE, Blomqvist M. Altered distribution of the gangliosides GM1 and GM2 in Alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 2012;33:174\u201388. https:\/\/doi.org\/10.1159\/000338181.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"966_CR43","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1083\/jcb.201208152","volume":"199","author":"FM Platt","year":"2012","unstructured":"Platt FM, Boland B, van der Spoel AC. The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J Cell Biol. 2012;199:723\u201334. https:\/\/doi.org\/10.1083\/jcb.201208152.","journal-title":"J Cell Biol"},{"key":"966_CR44","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1073\/pnas.1616152114","volume":"114","author":"SP Sardi","year":"2017","unstructured":"Sardi SP, Viel C, Clarke J, Treleaven CM, Richards AM, Park H, et al. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proc Natl Acad Sci U S A. 2017;114:2699\u2013704. https:\/\/doi.org\/10.1073\/pnas.1616152114.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"966_CR45","doi-asserted-by":"publisher","first-page":"8512","DOI":"10.1038\/s41598-019-44739-6","volume":"9","author":"MK Shin","year":"2019","unstructured":"Shin MK, Choi MS, Chae HJ, Kim JW, Kim HG, Kim KL. Ganglioside GQ1b ameliorates cognitive impairments in an Alzheimer\u2019s disease mouse model, and causes reduction of amyloid precursor protein. Sci Rep. 2019;9:8512. https:\/\/doi.org\/10.1038\/s41598-019-44739-6.","journal-title":"Sci Rep"},{"key":"966_CR46","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/ng1460","volume":"36","author":"MA Simpson","year":"2004","unstructured":"Simpson MA, Cross H, Proukakis C, Priestman DA, Neville DC, Reinkensmeier G, et al. Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase. Nat Genet. 2004;36:1225\u20139. https:\/\/doi.org\/10.1038\/ng1460.","journal-title":"Nat Genet"},{"key":"966_CR47","doi-asserted-by":"publisher","first-page":"572965","DOI":"10.3389\/fnins.2020.572965","volume":"14","author":"S Sipione","year":"2020","unstructured":"Sipione S, Monyror J, Galleguillos D, Steinberg N, Kadam V. Gangliosides in the brain: physiology, pathophysiology and therapeutic applications. Front Neurosci. 2020;14:572965. https:\/\/doi.org\/10.3389\/fnins.2020.572965.","journal-title":"Front Neurosci"},{"key":"966_CR48","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1159\/000063604","volume":"14","author":"L Svennerholm","year":"2002","unstructured":"Svennerholm L, Brane G, Karlsson I, Lekman A, Ramstrom I, Wikkelso C. Alzheimer disease - effect of continuous intracerebroventricular treatment with GM1 ganglioside and a systematic activation programme. Dement Geriatr Cogn Disord. 2002;14:128\u201336. https:\/\/doi.org\/10.1159\/000063604.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"966_CR49","doi-asserted-by":"publisher","first-page":"28110","DOI":"10.1074\/jbc.M414525200","volume":"280","author":"IY Tamboli","year":"2005","unstructured":"Tamboli IY, Prager K, Barth E, Heneka M, Sandhoff K, Walter J. Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide. J Biol Chem. 2005;280:28110\u20137. https:\/\/doi.org\/10.1074\/jbc.M414525200.","journal-title":"J Biol Chem"},{"key":"966_CR50","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1002\/jnr.23090","volume":"90","author":"G Wu","year":"2012","unstructured":"Wu G, Lu ZH, Kulkarni N, Ledeen RW. Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans. J Neurosci Res. 2012;90:1997\u20132008. https:\/\/doi.org\/10.1002\/jnr.23090.","journal-title":"J Neurosci Res"},{"key":"966_CR51","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1016\/j.bbamem.2008.07.028","volume":"1778","author":"N Yamamoto","year":"2008","unstructured":"Yamamoto N, Matsubara T, Sato T, Yanagisawa K. Age-dependent high-density clustering of GM1 ganglioside at presynaptic neuritic terminals promotes amyloid beta-protein fibrillogenesis. Biochim Biophys Acta. 2008;1778:2717\u201326. https:\/\/doi.org\/10.1016\/j.bbamem.2008.07.028.","journal-title":"Biochim Biophys Acta"},{"key":"966_CR52","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/s0197-4580(98)00032-3","volume":"19","author":"K Yanagisawa","year":"1998","unstructured":"Yanagisawa K, Ihara Y. GM1 ganglioside-bound amyloid beta-protein in Alzheimer\u2019s disease brain. Neurobiol Aging. 1998;19:S65\u20137. https:\/\/doi.org\/10.1016\/s0197-4580(98)00032-3.","journal-title":"Neurobiol Aging"},{"key":"966_CR53","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/nm1095-1062","volume":"1","author":"K Yanagisawa","year":"1995","unstructured":"Yanagisawa K, Odaka A, Suzuki N, Ihara Y. GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer\u2019s disease. Nat Med. 1995;1:1062\u20136. https:\/\/doi.org\/10.1038\/nm1095-1062.","journal-title":"Nat Med"},{"key":"966_CR54","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1093\/brain\/awu278","volume":"137","author":"DS Yang","year":"2014","unstructured":"Yang DS, Stavrides P, Saito M, Kumar A, Rodriguez-Navarro JA, Pawlik M, et al. Defective macroautophagic turnover of brain lipids in the TgCRND8 Alzheimer mouse model: prevention by correcting lysosomal proteolytic deficits. Brain. 2014;137:3300\u201318. https:\/\/doi.org\/10.1093\/brain\/awu278.","journal-title":"Brain"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-00966-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-00966-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-00966-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T09:04:02Z","timestamp":1643706242000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-00966-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["966"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-00966-0","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,1]]},"assertion":[{"value":"28 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving mice were performed using protocols approved by Sanofi Institutional Animal Care and Use Committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No data sets are from individuals. Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are current or former employees of Sanofi.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}